Diagonal Bio AB (publ) (NGM:DIABIO)

Diagonal Bio AB Statistics

Total Valuation

Diagonal Bio AB has a market cap or net worth of SEK 11.21 million. The enterprise value is 6.71 million.

Market Cap	11.21M
Enterprise Value	6.71M

Important Dates

The next estimated earnings date is Friday, August 22, 2025.

Earnings Date	Aug 22, 2025
Ex-Dividend Date	n/a

Share Statistics

Diagonal Bio AB has 1.40 billion shares outstanding. The number of shares has increased by 1,106.71% in one year.

Current Share Class	1.40B
Shares Outstanding	1.40B
Shares Change (YoY)	+1,106.71%
Shares Change (QoQ)	+90.05%
Owned by Insiders (%)	11.35%
Owned by Institutions (%)	3.10%
Float	1.20B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.26
PB Ratio	0.39
P/TBV Ratio	0.45
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.71
EV / Sales	4.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.45

Current Ratio	2.45
Quick Ratio	1.83
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-28.64

Financial Efficiency

Return on equity (ROE) is -40.60% and return on invested capital (ROIC) is -24.71%.

Return on Equity (ROE)	-40.60%
Return on Assets (ROA)	-19.37%
Return on Invested Capital (ROIC)	-24.71%
Return on Capital Employed (ROCE)	-32.49%
Revenue Per Employee	339,500
Profits Per Employee	-2.37M
Employee Count	5
Asset Turnover	0.05
Inventory Turnover	0.28

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -72.41% in the last 52 weeks. The beta is -1.89, so Diagonal Bio AB's price volatility has been lower than the market average.

Beta (5Y)	-1.89
52-Week Price Change	-72.41%
50-Day Moving Average	0.01
200-Day Moving Average	0.02
Relative Strength Index (RSI)	36.65
Average Volume (20 Days)	9,112,880

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Diagonal Bio AB had revenue of SEK 1.36 million and -9.47 million in losses. Loss per share was -0.02.

Revenue	1.36M
Gross Profit	1.03M
Operating Income	-9.22M
Pretax Income	-9.47M
Net Income	-9.47M
EBITDA	-8.74M
EBIT	-9.22M
Loss Per Share	-0.02

Balance Sheet

The company has 4.50 million in cash and n/a in debt, giving a net cash position of 4.50 million or 0.00 per share.

Cash & Cash Equivalents	4.50M
Total Debt	n/a
Net Cash	4.50M
Net Cash Per Share	0.00
Equity (Book Value)	28.39M
Book Value Per Share	0.02
Working Capital	3.79M

Cash Flow

Operating Cash Flow	-22.61M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	75.77%
Operating Margin	-679.16%
Pretax Margin	-697.35%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Diagonal Bio AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,106.71%
Shareholder Yield	n/a
Earnings Yield	-84.47%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Diagonal Bio AB has an Altman Z-Score of 0.57 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.57
Piotroski F-Score	1